Biospecifics Tech Cp (BSTC) 37.55 $BSTC AstraZe
Post# of 273258
Posted On: 09/02/2016 3:13:54 AM
Biospecifics Tech Cp (BSTC) 37.55 $BSTC
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 37.55 (+0.96), AZN: 32.60 (-0.21), OHRP: 2.77 (-0.09)
Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.55 (+0.96), DPRX: 12.79 (+0.09)
What Makes Collegium Pharmaceutical (COLL) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Collegium Pharmaceutical (COLL) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), COLL: 8.83 (+0.50)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 33.37 (-0.49), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), USNA: 136.35 (-0.39), TEVA: 50.90 (+0.51)
Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 33.37 (-0.49), ENDP: 20.23 (-0.47), VRX: 29.12 (+0.09), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), TEVA: 50.90 (+0.51), USNA: 136.35 (-0.39)
New Strong Buy Stocks for August 22nd
Tirthankar Chakraborty - Zacks Investment Research - Mon Aug 22, 7:36AM CDT
New Strong Buy Stocks for August 22nd
BSTC: 37.55 (+0.96), DTLK: 9.98 (+0.24), SNP: 71.34 (-0.03), COTV: 32.53 (-0.71), AEIS: 45.00 (+1.05)
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSTC: 37.55 (+0.96), CPRX: 0.96 (-0.05)
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 9, 2016 to report its second quarter 2016 financial results and to provide a corporate update.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 37.55 (+0.96)
New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 6.16 (unch), BSTC: 37.55 (+0.96), AZZ: 66.62 (+0.19), ASB: 19.68 (-0.16), AHT: 6.76 (-0.21)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01), RPRX: 2.00 (-0.03)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.45 (+0.01), ENDP: 20.23 (-0.47), BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08)
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 37.55 (+0.96), INCY: 80.81 (-0.29), ARQL: 1.40 (-0.08), ARIA: 10.19 (-0.15)
BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 37.55 (+0.96), AZN: 32.60 (-0.21), OHRP: 2.77 (-0.09)
Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.55 (+0.96), DPRX: 12.79 (+0.09)
What Makes Collegium Pharmaceutical (COLL) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Collegium Pharmaceutical (COLL) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), COLL: 8.83 (+0.50)
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 33.37 (-0.49), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), USNA: 136.35 (-0.39), TEVA: 50.90 (+0.51)
Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 33.37 (-0.49), ENDP: 20.23 (-0.47), VRX: 29.12 (+0.09), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), TEVA: 50.90 (+0.51), USNA: 136.35 (-0.39)
New Strong Buy Stocks for August 22nd
Tirthankar Chakraborty - Zacks Investment Research - Mon Aug 22, 7:36AM CDT
New Strong Buy Stocks for August 22nd
BSTC: 37.55 (+0.96), DTLK: 9.98 (+0.24), SNP: 71.34 (-0.03), COTV: 32.53 (-0.71), AEIS: 45.00 (+1.05)
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSTC: 37.55 (+0.96), CPRX: 0.96 (-0.05)
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 9, 2016 to report its second quarter 2016 financial results and to provide a corporate update.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 37.55 (+0.96)
BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 37.55 (+0.96)
New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 6.16 (unch), BSTC: 37.55 (+0.96), AZZ: 66.62 (+0.19), ASB: 19.68 (-0.16), AHT: 6.76 (-0.21)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01), RPRX: 2.00 (-0.03)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.45 (+0.01), ENDP: 20.23 (-0.47), BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08)
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 37.55 (+0.96), INCY: 80.81 (-0.29), ARQL: 1.40 (-0.08), ARIA: 10.19 (-0.15)
BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)
(0)
(0)Scroll down for more posts ▼